Risk analysis is not yet available for this country's tenders. Currently supported: Estonia, Latvia, Lithuania, Poland, France, UK, Denmark, Netherlands, Norway, and Finland.
Get an AI-powered winning strategy tailored to this tender. Includes win probability score, key opportunities and challenges, recommended bid focus areas, competitive positioning insights, and actionable recommendations to maximize your chances.
LoginUpgrade to see which companies are likely to bid on this tender, based on historical procurement data.
LoginAI extracts and organizes all requirements from tender documents — mandatory qualifications, technical specifications, financial conditions, and submission rules — clearly categorized so you know exactly what's needed to bid.
Login3 documents available with AI summaries
This OCDS record confirms the award of a contract by Gloucestershire Hospitals NHS Foundation Trust for Oncotype DX Breast Recurrence Score testing under the Provider Selection Regime, indicating the opportunity has already been fulfilled.
This OCDS Release Package serves as a confirmation of a contract award under the Provider Selection Regime for the provision of Oncotype DX Breast Recurrence Score testing, detailing the awarded contract for pathology services.
This document is a contract award notice from Gloucestershire Hospitals NHS Foundation Trust for the provision of Oncotype DX Breast Recurrence Score testing, valued at £214,650, awarded to Exact Science for the period of July 2025 to June 2026.
Sign up to view document summaries and analysis
Comprehensive quality analysis of this tender scoring legal compliance, clarity, completeness, fairness, practicality, data consistency, and sustainability on a 0-100 scale with detailed breakdown and recommendations.
LoginHello! I'm your AI assistant for this tender. I can help you understand requirements, deadlines, eligibility criteria, and provide strategic insights.
No credit card required